Oncolytics Biotech Inc Earnings

The next earnings date for Oncolytics Biotech Inc is March 5, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Oncolytics Biotech Inc Earnings

Report DateEstimated Earnings Per Share
05/01/2026$-0.08
03/05/2026$-0.08

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Oncolytics Biotech Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
11/12/2025---$0100.00%
08/08/2025---$-0.0720.90%
05/07/2025Before Market$-0.0811.11%
03/05/2025Before Market$-0.1025.65%
11/04/2024Before Market$-0.09-29.71%
08/01/2024After Market$-0.100.00%
05/09/2024After Market$-0.0918.18%
03/07/2024After Market$-0.0566.67%
11/03/2023Before Market$-0.14-40.00%
08/14/2023Before Market$-0.12-9.09%
05/05/2023Before Market$-0.1023.08%
03/03/2023Before Market$-0.15-50.00%
11/07/2022Before Market$-0.0827.27%
08/11/2022Before Market$-0.0918.18%
05/05/2022After Market$-0.1220.00%
03/02/2022After Market$-0.14-7.69%
11/05/2021Before Market$-0.0935.71%
08/06/2021Before Market$-0.13-8.33%
05/07/2021Before Market$-0.1323.53%
03/05/2021Before Market$-0.22-46.67%
11/11/2020After Market$-0.16-14.29%
08/04/2020After Market$-0.17-21.43%
05/08/2020Before Market$0.12163.16%
03/05/2020After Market$-0.25-66.67%
11/12/2019After Market$-0.1534.78%
08/13/2019After Market$-0.26-4.00%
05/03/2019Before Market$-0.276.90%
03/08/2019Before Market$-0.28-16.67%
11/12/2018Before Market$-0.2025.93%
08/03/2018Before Market$-0.27-640.00%
05/11/2018Before Market$-0.28-47.37%
03/09/2018Before Market$-0.38-35.71%
11/08/2017Before Market$-0.1942.42%
08/03/2017Before Market$-0.280.00%
05/05/2017Before Market$-0.2826.32%
03/10/2017Before Market$-0.47-67.86%
11/03/2016Before Market$-0.28-1,300.00%
08/04/2016Before Market$-0.1932.14%
05/06/2016Before Market$-0.0293.52%
03/11/2016Before Market$-0.2826.32%
11/05/2015Before Market$-0.1942.42%
08/06/2015Before Market$-0.2826.32%
05/07/2015Before Market$-0.380.00%
03/16/2015After Market$-0.3833.33%
11/06/2014Before Market$-0.4722.95%
08/07/2014---$-0.4728.79%
05/08/2014---$-0.5713.64%
03/13/2014---$-0.6618.52%
11/07/2013---$-0.660.00%
08/01/2013---$-0.5734.48%
05/09/2013---$-0.7610.59%
03/14/2013---$-1.040.95%
11/08/2012---$-1.14-6.54%
08/02/2012---$-1.24-9.73%
05/10/2012---$-1.0415.45%
03/15/2012---$-1.52-58.33%
11/10/2011---$-0.8515.84%
07/28/2011---$-0.854.49%
05/12/2011---$-0.5730.49%
03/17/2011---$-1.14-28.09%
11/10/2010---$-0.6623.26%
07/29/2010---$-0.6622.35%
05/12/2010---$-0.6622.35%
03/09/2010---$-0.85-54.55%
11/05/2009---$-0.4730.88%
07/29/2009---$-0.76-4.11%
05/07/2009---$-0.85-3.66%
03/04/2009---$-0.8519.05%
11/04/2008---$-0.955.94%
07/29/2008---$-1.24-25.25%
04/30/2008---$-0.7626.92%
03/06/2008---$-0.8510.53%
10/30/2007---$-0.83---
07/27/2007---$-0.77---
04/27/2007---$-0.87---
03/02/2007---$-1.12---
11/03/2006---$-0.80---
07/26/2006---$-0.70---
04/26/2006---$-0.68---
03/03/2006---$-0.97---
10/26/2005---$-0.850.00%
07/27/2005---$-0.69---
04/27/2005---$-0.57---
02/15/2005---$-1.52-60.00%
10/26/2004---$-0.76---
08/05/2004---$-0.77---
04/27/2004---$-0.71---
03/08/2004---$-0.43---
11/03/2003---$-0.50---
08/05/2003---$-1.19---
03/31/2003---$-0.32---
06/30/2002---$-0.40---

More About Oncolytics Biotech Inc

Website
https://oncolyticsbiotech.com
Country
USA
Full Time Employees
28

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

“Oncolytics Biotech Inc Earnings” Can Refer to the Oncolytics Biotech Inc Earnings Date

Some people say “Oncolytics Biotech Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Oncolytics Biotech Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Oncolytics Biotech Inc Stock on the Earnings Date

If you own Oncolytics Biotech Inc stock (ONCY) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Oncolytics Biotech Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Oncolytics Biotech Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Oncolytics Biotech Inc Earnings

You can contact us any time if you would like to ask questions about Oncolytics Biotech Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.